Calcitonin Gene-Related Peptide In Vivo Positive Inotropy Is Attributable to Regional Sympatho-Stimulation and Is Blunted in Congestive Heart Failure
- 4 February 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 96 (2) , 234-243
Abstract
Calcitonin gene-related peptide (CGRP) is a nonadrenergic/noncholinergic (NANC) peptide with vasodilatative/inotropic action that may benefit the failing heart. However, precise mechanisms for its in vivo inotropic action remain unclear. To assess this, dogs with normal or failing (sustained tachypacing) hearts were instrumented for pressure–dimension analysis. In control hearts, CGRP (20 pmol/kg per minute) enhanced cardiac contractility (eg, +33±4.2% in end-systolic elastance) and lowered afterload (−14.2±2% in systemic resistance, both P P <0.001 versus control), whereas arterial dilation remained unaltered (−19.3±5%). CGRP-positive inotropy was not attributable to reflex activation because similar changes were observed in the presence of a ganglionic blocker. However, it was fully prevented by the β-receptor antagonist (timolol), identifying a dominant role of sympatho-stimulatory signaling. In control hearts, myocardial interstitial norepinephrine assessed by microdialysis almost doubled in response to CGRP infusion, whereas systemic plasma levels were unchanged. In addition, CGRP receptors were not observed in ventricular myocardium but were prominent in coronary arteries and the stellate ganglia. Ventricular myocytes isolated from normal and failing hearts displayed no inotropic response to CGRP, further supporting indirect sympatho-stimulation as the primary in vivo mechanism. In contrast, the peripheral vasodilatative capacity of CGRP was similar in femoral vascular rings from normal and failing hearts in dogs. Thus, CGRP-mediated positive inotropy is load-independent but indirect and attributable to myocardial sympathetic activation rather than receptor-coupled stimulation in canine hearts. This mechanism is suppressed in heart failure, so that afterload reduction accounts for CGRP-enhanced function in this setting.Keywords
This publication has 37 references indexed in Scilit:
- Calcitonin receptor-like receptor: identification and distribution in human peripheral tissuesCell and tissue research, 2002
- Increased myocardial expression of RAMP1 and RAMP3 in rats with chronic heart failureBiochemical and Biophysical Research Communications, 2002
- Regional Localization and Abundance of Calcitonin Gene-Related Peptide Receptors in Guinea Pig HeartJournal of Molecular and Cellular Cardiology, 2001
- Neuropeptide variability in manEuropean Journal of Clinical Investigation, 2000
- Reduced capacity of cardiac efferent sympathetic neurons to release noradrenaline and modify cardiac function in trachycardia-induced canine heart failureCanadian Journal of Physiology and Pharmacology, 1996
- β‐ADRENOCEPTOR DESENSITIZATION DURING THE DEVELOPMENT OF CANINE PACING‐INDUCED HEART FAILUREClinical and Experimental Pharmacology and Physiology, 1996
- Non-adrenergic non-cholinergic (NANC) neural control of the atrial myocardiumGeneral Pharmacology: The Vascular System, 1993
- Effect of Calcitonin Gene-Related Peptide on Well-Developed Canine Coronary Collateral VasculatureJournal of Cardiovascular Pharmacology, 1993
- Calcitonin gene-related peptide: a haemodynamic study of a novel vasodilator in patients with severe chronic heart failureInternational Journal of Cardiology, 1992
- The first demonstration of CGRP-immunoreactive fibers in canine hearts: Coronary vasodilator, inotropic and chronotropic effects of CGRP in canine isolated, blood-perfused heart preparations.The Japanese Journal of Pharmacology, 1989